Develops a high-throughput transcriptomic sequencing platform that generates chemotranscriptomes to map chemical interactions to biological networks. This technology enables the discovery of potential drugs targeting chronic diseases, including cancer, chronic kidney disease, and neurodegeneration, by addressing challenges like drug resistance.

Atea Pharmaceuticals is developing oral direct-acting antiviral therapies, specifically bemnifosbuvir and ruzasvir, for the treatment of hepatitis C virus (HCV) and COVID-19. The company targets the unmet medical need for effective antiviral treatments, as millions of HCV patients remain untreated despite the availability of therapies.

Develops personalized cytokine-based therapies using a proprietary Diakine™ platform that combines anti-inflammatory and immune-stimulating cytokines to target cancer and inflammatory diseases. This approach enriches affected tissues with tailored cytokine combinations, aiming to control disease while minimizing toxic inflammation, offering a precision medicine solution for individual patient immune responses.

Iridia utilizes Molecular Avatar Technology to embed unalterable molecular identities into products, ensuring authenticity and traceability without altering their appearance or functionality. This technology addresses counterfeiting and enhances supply chain visibility across various industries, including luxury retail and aerospace.

Marius Pharmaceuticals develops KYZATREX, an oral testosterone undecanoate therapy absorbed primarily via the lymphatic system, designed to treat adult men with hypogonadism, a condition characterized by low testosterone levels. This therapy addresses the significant health impacts of testosterone deficiency, including fatigue, decreased libido, and increased risk of metabolic disorders, by restoring testosterone levels to the normal range in a majority of patients.

Pria is a HIPAA-compliant technology platform that integrates remote care solutions for chronic condition management, enabling healthcare organizations to deliver these services at scale. By improving patient engagement and adherence, Pria addresses the inefficiencies in remote care that lead to significant healthcare costs and poor health outcomes.

Triumvira Immunologics develops T cell therapies using its proprietary T cell Antigen Coupler (TAC) platform, which enhances T cell activation to target and destroy cancer cells across various tumor types. This approach addresses the challenge of treating difficult-to-manage cancers by leveraging the body's natural immune response for improved therapeutic outcomes.

Walden Biosciences is developing targeted gene editing therapies to modify renal cell function in patients with chronic kidney disease. This approach aims to improve patient outcomes by reducing reliance on dialysis and kidney transplants.